Solvay Pharma
Solvay Pharma, a prominent division of Solvay Group, is headquartered in France and operates extensively across Europe, North America, and Asia. Established in 1995, the company has made significant strides in the pharmaceutical industry, focusing on innovative treatments in areas such as central nervous system disorders, women's health, and rare diseases. Renowned for its commitment to research and development, Solvay Pharma offers a range of unique products that address unmet medical needs, setting it apart in a competitive market. With a strong emphasis on sustainability and patient-centric solutions, the company has achieved notable recognition for its contributions to healthcare. As a key player in the pharmaceutical landscape, Solvay Pharma continues to advance its mission of improving patient outcomes through cutting-edge therapies.
DitchCarbon Score
How does Solvay Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Solvay Pharma's score of 26 is lower than 51% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Solvay Pharma's reported carbon emissions
As of the latest available data, Solvay Pharma does not report any specific carbon emissions figures, indicating a lack of publicly disclosed emissions data. Consequently, there are no recorded Scope 1, 2, or 3 emissions figures to analyse. Additionally, there are no documented reduction targets or climate commitments, such as those aligned with the Science Based Targets initiative (SBTi) or other industry standards. In the absence of specific emissions data and reduction initiatives, it is important to note that many pharmaceutical companies are increasingly focusing on sustainability and climate action. This trend often includes commitments to reduce greenhouse gas emissions, improve energy efficiency, and transition to renewable energy sources. However, without specific commitments or data from Solvay Pharma, it is challenging to provide a detailed overview of their climate strategy. Overall, while Solvay Pharma may be part of a broader industry movement towards sustainability, the lack of disclosed emissions data and reduction targets limits the ability to assess their specific climate commitments at this time.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Solvay Pharma is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
